Mesenchymal Stem Cells Market: North America Dominated And Accounted For The Largest Revenue Share

 Mesenchymal Stem Cells Industry Overview

The global mesenchymal stem cells market size is expected to reach USD 6.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.6% from 2021 to 2028. Mesenchymal stem cells (MSCs) are set to gain popularity among healthcare professionals, to develop novel therapeutics, primarily targeted at the treatment of several immune-mediated disorders. MSCs have been acclaimed effective as a regenerative therapy for skeletal tissue repair and have recently gained traction across modulation of immune cells and endogenous tissues.

 

Expanding clinical applications of mesenchymal stem cells, strengthening the pipeline of these therapies, along with intensifying market competition are some of the key aspects driving the industry expansion of MSCs. The recent pandemic outbreak of COVID-19 is set to propel the clinical applications and investments done in this market space. For instance, in April 2020, Canada’s The Stem Cell Network (SCN) provided funding of USD 300,000 to the project targeted towards the evaluation of optimal dosage of MSCs, to design an effective therapeutic approach to reduce the impacts of respiratory disorders associated with SARS-CoV-2 infection.

Additionally, as stated by clinicaltrials.gov, 21 clinical trials reportedly incorporated MSCs in the management of COVID-19. Apart from the applications of MSCs in regenerative medicine and tissue engineering, the MSCs serve as a potent therapeutic approach for cancer treatment. As of February 2020, 25 clinical trials have been registered that employ MSCs in the treatment of several cancer indications. This is set to drive the mesenchymal stem cells market (MSCs) market.

Acknowledging the profitable opportunities posed by the market, key industry participants are focused towards initiating technological collaborations to strengthen their market presence. In August 2020, NantKwest Inc. collaborated with Generate Life Sciences Co. to develop a mesenchymal stem cell-based treatment against COVID-19. The latter company is providing with the MSCs derived from donated umbilical cord tissues.

Mesenchymal Stem Cells Market Segmentation

Grand View Research has segmented the global mesenchymal stem cells market on the basis of products and services, type, source of isolation, indication, application, and region:

Based on the Products & Services Insights, the market is segmented into Products, and Services.

• The products segment dominated the market and accounted for the largest revenue share of 79.1% in 2020. Among the products, the cells and cell lines segment has emerged as a key contributor to the segment’s revenue. Several market players are engaged in capturing untapped avenues of this market space by undertaking various initiatives such as new product development, business expansion.

 

• The kits, media, and reagents segment is expected to register the highest growth rate of 13.4% from 2021 to 2028. Expanding product lines by competitors serves as the key attributive factor to the segment’s fast-paced growth. In March 2020, researchers from China developed a full chemical-defined medium - NBVbe medium that supports the isolation of human MSCs. This new product is expected to aid the optimization of MSC medium, molecular characterization, and clinical applications.

 

Based on the Type Insights, the market is segmented into Autologous, and Allogeneic.

• The allogeneic MSCs segment dominated the market and accounted for the largest revenue share of 54.3% in 2020. This is attributed to the high safety profile of allogeneic mesenchymal stem cells in clinical applications. Additionally, implantation of allogeneic MSCs is set to emerge as a pioneering cell-based therapeutic approach owing to the associated low immunogenicity coupled with immunosuppressive properties.

 

• The use of autologous mesenchymal stem cells has undergone various advances in the past few years. The segment is expected to register a CAGR of 13.2% over the forecast period. Various studies are being conducted using autologous MSCs for the treatment of various diseases.

 

Based on the Source of Isolation Insights, the market is segmented into Bone Marrow, Cord Blood, Peripheral Blood, Fallopian Tube, Fetal Liver, Lung, and Adipose Tissues.

• The bone marrow segment dominated the market and accounted for the largest revenue share of 25.8% in 2020. Bone marrow is a major source of isolation for mesenchymal stem cells. These cells have multilineage differentiation potential and are able to differentiate into bones, cartilage, tendons, fibroblasts, fat, cardiac muscle cells, and endothelial cells.

 

• MSCs derived from adipose tissues have pegged the second position in the market in terms of revenue share. The segment is expected to register a CAGR of 12.9% over the forecast period. These offer multipotent mesenchymal stem cells exhibiting several advantages across extraction, isolation, and expansion along with robust cell concentration.

 

Based on the Indication Insights, the market is segmented into Bone And Cartilage Repair, Cardiovascular Disease, Inflammatory And Immunological Diseases, Liver Diseases, Cancer, GvHD, and Others.

• The cardiovascular diseases segment dominated the Mesenchymal Stem Cells (MSCs) market and accounted for the largest revenue share of 22.0% in 2020. Several pre-clinical studies have shown that the transplantation of mesenchymal stem cells improves cardiovascular repair, which has strengthened the penetration of MSCs in cardiovascular disease indications.

 

• This has gained significant traction across clinical applications associated with the Graft versus Host Disease (GvHD), contributing to the highest growth rate of 14.4% from 2021 to 2028. In addition, since the last decade, oncology applications of cell therapies have witnessed rapid developments with the MSCs at the forefront.

 

Based on the Application Insights, the market is segmented into Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies, and Others.

• The disease modelling application segment dominated the market and accounted for the largest revenue share of 35.8% in 2020. The use of cellular disease models with patient-specific MSCs provides an ideal tool for pathological research. The mesenchymal stem cells derived from patient Induced Pluripotent Stem Cells serve as a potential disease modelling tool.

 

• The tissue engineeringapplication segment is set to grow at a rapid pace of 13.4% from 2021 to 2028. Mesenchymal stem cells have emerged as a promising therapeutic approach in tissue engineering. Owing to their high capacity of expansion, self-renewal, and reduced tumorigenic capacity, these cells have widespread applications. 

 

Mesenchymal Stem Cells Regional Outlook

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa (MEA)

 

Key Companies Profile & Market Share Insights

Market players are focused on the expansion of their offerings through extensive R&D and the formation of alliances and partnerships with other major players to sustain their market position. Owing to the recent pandemic of COVID-19, several research and academic research institutes are making focused efforts to develop a treatment regime by using mesenchymal stem cells.

For instance, in April 2020, a team of US researchers received the U.S. FDA approval to initiate the clinical trial for the evaluation of umbilical cord-derived mesenchymal stem cells to prevent lung inflammation in severe cases of COVID-19 infection. On the other hand, in August 2019, Bayer AG invested USD 600 million to acquire BlueRock Therapeutics to strengthen its market presence in stem cell therapies. Such notable mergers and acquisitions are anticipated to support market growth. Some of the prominent players in the mesenchymal stem cells market include:

• Thermo Fisher Scientific, Inc.
• Cell Applications, Inc.
• Axol Biosciences Ltd.
• Cytori Therapeutics Inc
• STEMCELL Technologies Inc
• Cyagen Biosciences Inc.
• Celprogen Inc
• BrainStorm Cell Therapeutics Inc.
• Stemedica Cell Technologies Inc
• Merck KGaA (MilliporeSigma)
• Smith+Nephew
• Lonza AG
• PromoCell GmbH
• ScienCell Research Laboratories
• American Type Culture Collection

 

Order a free sample PDF of the Mesenchymal Stem Cells Market Intelligence Study, published by Grand View Research.

 

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

 

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com

Follow Us: LinkedIn | Twitter